Helix BioPharma ( (TSE:HBP) ) just unveiled an announcement.
Helix BioPharma Corp. has announced the extension of its Annual General and Special Meeting to March 26, 2025, to allow more time for shareholder approval of proposed asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG, as well as a proposed financing strategy. This extension, approved by the Ontario Superior Court of Justice, is a strategic move to strengthen the company’s asset base and financial positioning, potentially impacting its market standing and stakeholder interests.
More about Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing treatments for hard-to-treat cancers. The company operates in the biotechnology industry and is engaged in shaping a future where such cancers can be effectively managed.
YTD Price Performance: 10.11%
Average Trading Volume: 4,923
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$51.96M
For an in-depth examination of HBP stock, go to TipRanks’ Stock Analysis page.